Effect of Vitamin D Supplementation on Progression of Knee Pain and Cartilage Volume Loss in Patients With Symptomatic Osteoarthritis: A Randomized Controlled Trial | Geriatrics | JAMA | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.237.124.210. Please contact the publisher to request reinstatement.
Original Contribution
January 9, 2013

Effect of Vitamin D Supplementation on Progression of Knee Pain and Cartilage Volume Loss in Patients With Symptomatic Osteoarthritis: A Randomized Controlled Trial

Author Affiliations

Author Affiliations: Division of Rheumatology, Tufts Medical Center, Boston, Massachusetts (Drs McAlindon and Lee and Ms Nuite); Boston University School of Public Health, Crosstown Center, Boston, Massachusetts (Dr LaValley); Imaging Institute, Cleveland Clinic Foundation, Cleveland, Ohio (Dr Schneider); Biostatistics Research Center in the Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts (Ms Price); Michael E. DeBakey Veterans Affairs Medical Center, Medical Care Line and Research Care Line; Houston VA Health Services Research and Development Center of Excellence, and Section of Immunology, Allergy, and Rheumatology, Department of Medicine, Baylor College of Medicine, Houston, Texas (Dr Lo); Jean Mayer USDA Human Nutrition Research Center on Aging, at Tufts University, Boston, Massachusetts (Dr Dawson-Hughes).

JAMA. 2013;309(2):155-162. doi:10.1001/jama.2012.164487
Abstract

Importance Knee osteoarthritis (OA), a disorder of cartilage and periarticular bone, is a public health problem without effective medical treatments. Some studies have suggested that vitamin D may protect against structural progression.

Objective To determine whether vitamin D supplementation reduces symptom and structural progression of knee OA.

Design, Setting, and Patients A 2-year randomized, placebo-controlled, double-blind, clinical trial involving 146 participants with symptomatic knee OA (mean age, 62.4 years [SD, 8.5]; 57 women [61%], 115 white race [79%]). Patients were enrolled at Tufts Medical Center in Boston between March 2006 and June 2009.

Intervention Participants were randomized to receive either placebo or oral cholecalciferol, 2000 IU/d, with dose escalation to elevate serum levels to more than 36 ng/mL.

Main Outcome Measures Primary outcomes were knee pain severity (Western Ontario and McMaster Universities [WOMAC] pain scale, 0-20: 0, no pain; 20, extreme pain), and cartilage volume loss measured by magnetic resonance imaging. Secondary end points included physical function, knee function (WOMAC function scale, 0-68: 0,  no difficulty; 68, extreme difficulty), cartilage thickness, bone marrow lesions, and radiographic joint space width.

Results Eighty-five percent of the participants completed the study. Serum 25-hydroxyvitamin D levels increased by a mean 16.1 ng/mL (95% CI, 13.7 to 18.6) in the treatment group and by a mean 2.1 mg/mL (95% CI, 0.5 to 3.7) (P < .001) in the placebo group. Baseline knee pain was slightly worse in the treatment group (mean, 6.9; 95% CI, 6.0 to 7.7) than in the placebo group (mean, 5.8; 95% CI, 5.0 to 6.6) (P = .08). Baseline knee function was significantly worse in the treatment group (mean, 22.7; 95% CI, 19.8 to 25.6) than in the placebo group (mean, 18.5; 95% CI, 15.8 to 21.2) (P = .04). Knee pain decreased in both groups by a mean −2.31 (95% CI, −3.24 to −1.38) in the treatment group and −1.46 (95% CI, −2.33 to −0.60) in the placebo group, with no significant differences at any time. The percentage of cartilage volume decreased by the same extent in both groups (mean, −4.30; 95% CI, −5.48 to −3.12 vs mean, −4.25; 95% CI, −6.12 to −2.39) (P = .96). There were no differences in any of the secondary clinical end points.

Conclusion and Relevance Vitamin D supplementation for 2 years at a dose sufficient to elevate 25-hydroxyvitamin D plasma levels to higher than 36 ng/mL, when compared with placebo, did not reduce knee pain or cartilage volume loss in patients with symptomatic knee OA.

Trial Registration clinicaltrials.gov Identifier: NCT00306774

×